Care pathway for Monoclonal Antibody Therapy of Severe Eosinophilic Asthma The use of Monoclonal Antibody (Mab) therapy is relatively new and evolving, but promises to revolutionise the management of asthma. This study by AstraZeneca has demonstrated the value of appraising the sustainability of care pathways using SHC’s guidance. The assessment has identified the environmental hotspots Continue reading “Care pathway for Monoclonal Antibody Therapy”
Resource Type Archives
Decarbonisation of CKD treatment in the UAE
A discussion paper. It is recognised that global health and care systems are undergoing transformative change to adapt to the needs of patients and communities, with increasing pressure to be financially, socially and environmentally sustainable. Appraising the sustainability of care pathways is seen as a crucial step to enabling a more sustainable health system. As Continue reading “Decarbonisation of CKD treatment in the UAE”
Building environmental considerations into the evaluation of health interventions
The past decade has seen encouraging commitments from health system leaders, professional societies and industry to identifying environmentally sustainable practices that can be built into the future of healthcare. Making these commitments a reality will require accurate ways of measuring the environmental impact of health interventions, as well as transparent decision-making frameworks to guide how Continue reading “Building environmental considerations into the evaluation of health interventions”
Balancing Sustainability and Access: The Future of Off-Patent Medicines
The off-patent medicines industry is a cornerstone of European healthcare, accounting for 70% of medicines dispensed in Europe. These drugs treat a range of severe conditions, including cancer, respiratory diseases, and autoimmune disorders, forming an essential part of health systems. However, the significant economic and health impact of the off-patent medicines industry comes with great Continue reading “Balancing Sustainability and Access: The Future of Off-Patent Medicines”
Sustainable Procurement in Healthcare
Sustainable Procurement in Healthcare It has been shown that supply chains contribute a significant proportion of the overall impact of our healthcare systems on the environment and to our society and is a focus of effort for healthcare systems globally. But there is a perception that supply chain management isn’t achieving as much as it Continue reading “Sustainable Procurement in Healthcare”
Waste Benefits of a Reusable IoL Inserter in Cataract Surgery
Cataract surgery holds the title of the most frequently conducted surgical procedure globally. In the UK alone, Optegra – a provider of eye healthcare for the NHS – performs an average of 25 cataract surgeries per surgeon daily at each of their ~19 sites. This high volume requires significant daily supply deliveries, increasing the environmental Continue reading “Waste Benefits of a Reusable IoL Inserter in Cataract Surgery”
Climate footprint of industry-sponsored in-human clinical trials: life cycle assessments of clinical trials spanning multiple phases and disease areas
BMJ | Feb 2025 | “This study aims to calculate the global warming potential, in carbon dioxide (CO2) equivalent emissions, from all in-scope activities involved in phase 1, 2, 3 and 4 clinical trials spanning multiple disease areas.”
Open Letter to Clinical Trial Community published by members of the Sustainable Markets Initiative Health Systems Task Force
SMI | Feb 2025 “CEOs from AstraZeneca, GSK, Merck, Novo Nordisk, Novartis, Sanofi and Roche have signed the letter”
The Sustainable Healthcare Podcast
We sit down with the Sustainable Healthcare Coalition (SHC) to unpack what it really takes to decarbonize healthcare
What is the carbon footprint of academic clinical trials? A study of hotspots in 10 trials
BMJ | Oct 2024 “Clinical trials are fundamental to healthcare, however, they also contribute to anthropogenic climate change..”
